A research breakdown of Epitalon, NAD+, GHK-Cu, and MOTS-C — four compounds, four distinct mechanisms.
Longevity research operates at a cellular level that's harder to visualize than the effects studied in recovery or metabolic peptide research. There's no single biomarker that captures biological aging the way fasting glucose captures metabolic health or tendon cross-sectional area captures repair. What researchers have instead is a set of cellular processes, including telomere maintenance, mitochondrial function, DNA repair, and oxidative stress response, that correlate with aging across species and models.
The four compounds in Lumé's longevity category each address one or more of these processes through distinct mechanisms. They aren't interchangeable, and they don't all work the same way. Understanding what each one actually does in research models is the starting point for any serious protocol design.
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology, where it's been studied since the 1980s. The original research identified it as an extract component of the pineal gland, and early work focused on its effects on melatonin secretion and circadian rhythm regulation in aging animal models.
The research trajectory shifted when Epitalon was found to activate telomerase in human cell culture studies. Telomerase is the enzyme responsible for maintaining telomere length. Telomeres are the protective caps on chromosomes that shorten with each cell division. Their progressive shortening is one of the most well-documented markers of cellular aging, and telomere length in peripheral blood cells correlates with mortality risk across several longitudinal human studies.
The Khavinson group published extensively on Epitalon across several decades, including studies showing increased telomere length in treated cell cultures, life extension in fruit fly and rodent models, and reductions in age-related pathology markers in older animal subjects. The research base is real, though much of it comes from a single institutional group, which means independent replication is more limited than for other compounds in this category.
In research settings, Epitalon is typically studied in short concentrated cycles rather than continuous administration, which is reflected in most protocol designs that reference this compound.
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every cell of the body. It functions as an electron carrier in metabolic reactions and serves as a substrate for several enzyme families critical to cellular maintenance. The most studied of these are the sirtuins (SIRT1-7), a class of NAD+-dependent deacetylases that regulate gene expression, DNA repair, mitochondrial biogenesis, and inflammation response.
NAD+ levels decline with age across species. In rodent models, this decline correlates with deterioration in mitochondrial function, reduced DNA repair capacity, and increased inflammatory signaling. Restoring NAD+ levels in older rodents reverses several of these markers. Studies in aged mice using NAD+ precursors have shown improvements in muscle function, metabolic efficiency, and cognitive performance relative to untreated controls.
Direct NAD+ supplementation bypasses the precursor conversion pathway entirely. Research on direct administration focuses primarily on bioavailability and the comparison of different delivery routes in terms of achieving tissue-level NAD+ elevation. Published data suggests that intravenous or subcutaneous administration raises NAD+ levels more reliably than oral routes, which are subject to significant first-pass degradation.
NAD+ research intersects with mitochondrial health, inflammation research, and metabolic regulation. It's one of the most studied molecules in the aging biology literature, which gives it a depth of research context that newer longevity compounds don't yet have.
GHK-Cu (copper tripeptide, Gly-His-Lys complexed with copper) was first isolated from human plasma in 1973 by Loren Pickart, who identified it as a fragment that stimulated liver tissue regeneration in culture. Subsequent research expanded its studied effects considerably: wound healing, collagen and elastin synthesis, anti-inflammatory gene regulation, antioxidant enzyme upregulation, and nervous system protection in injury models.
The copper component is central to GHK-Cu's activity. Copper is a cofactor for several key enzymes involved in connective tissue synthesis and antioxidant defense. GHK functions as a carrier that delivers copper to specific cellular compartments where it activates these pathways. The tripeptide alone has different (and generally weaker) biological activity than the copper-complexed form.
Gene expression research on GHK-Cu is particularly notable. Pickart's later work and several independent groups identified GHK-Cu as a potent regulator of gene expression, with the compound upregulating hundreds of genes associated with tissue repair, anti-aging responses, and cellular protection while downregulating genes associated with inflammation, cancer progression, and aging pathology. The magnitude of gene expression effects observed in vitro is unusual for a tripeptide and has generated ongoing research interest.
GHK-Cu at 100mg provides enough material for extended research protocols studying wound healing, collagen synthesis, and systemic antioxidant response. The Lumé formulation is lyophilized and priced at $135 per vial.
MOTS-C is the newest compound in this category and arguably the most mechanistically interesting. It's a mitochondria-derived peptide, meaning it's encoded by mitochondrial DNA rather than nuclear DNA. This is unusual. Most signaling peptides are nuclear-encoded. MOTS-C's mitochondrial origin means it's part of a communication system between mitochondria and the rest of the cell, a system that's been largely unexplored until the past decade.
Discovered by Changhan David Lee's group at the University of Southern California in 2015, MOTS-C was found to be a regulator of metabolic homeostasis via AMPK activation. AMPK (AMP-activated protein kinase) is sometimes described as the cell's energy sensor. When energy is low, AMPK is activated and triggers a cascade of responses that increase glucose uptake, stimulate fatty acid oxidation, improve insulin sensitivity, and trigger mitochondrial biogenesis.
In research models, MOTS-C administration has shown:
MOTS-C also appears to translocate to the nucleus under stress conditions, where it directly regulates gene expression related to cellular stress response. This makes it functionally distinct from most other metabolic peptides, which work primarily through surface receptors.
Lumé carries MOTS-C in both the longevity category and the fat loss and metabolic category, reflecting its dual documented effects on cellular aging and energy metabolism.
The four compounds address aging biology from different angles without significant mechanistic overlap. Epitalon works at the chromosomal level through telomerase. NAD+ works at the metabolic and epigenetic level through sirtuin activation. GHK-Cu works at the gene expression and tissue maintenance level through copper-dependent pathways. MOTS-C works at the mitochondrial communication and energy sensing level through AMPK.
Research protocols that include multiple compounds from this group are studying different cellular processes simultaneously. That's not redundancy, it's coverage. The biology of aging is multifactorial, and each of these targets a different component of that process.
What connects Epitalon, NAD+, GHK-Cu, and MOTS-C isn't a shared mechanism. It's a shared research focus: understanding and intervening in the cellular processes that define biological aging.
All products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. These statements and products are not intended to diagnose, treat, cure, or prevent any disease. Lumé Longevity LLC is a chemical supplier and is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Not an outsourcing facility as defined under 503B. All products are sold for research, laboratory, or analytical purposes only.